The aminothiazolyl-cephalosporin RU 29 246 is the active metabolite of the prodrugpivaloyl-oxyethyl-ester HR 916. RU 29 246 in vitro activity includes a wide range of clinically relevant bacterial pathogens. Against methicillin-sensitive Staphylococci RU 29 246 (MIC90 of 0.25 -2 /ig/ ml) was clearly more active than cefaclor, cefuroxime, cefpodoxime, cefixime and ceftibuten, but slightly less active than cefdinir. RU29 246 inhibited hemolytic Streptococci of the serogroups A, B, C and G as well as penicillin-sensitive Streptococcus pneumoniae at concentrations similar to cefdinir, cefpodoxime and cefuroxime (MIC9O<0.13jug/ml), but less than the other oral cephalosporins investigated (cefixime, cefaclor and ceftibuten).
to cefdinir, cefpodoxime and cefuroxime (MIC9O<0.13jug/ml), but less than the other oral cephalosporins investigated (cefixime, cefaclor and ceftibuten).
MIC90s of RU 29 246 against
Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Salmonella spp., Shigella spp., Proteus mirabilis and Haemophilus influenzae were < 0.5 jug/ml. Only RU29 246 and cefdinir demonstrated moderate activity against Acinetobacter baumannii (MIC90 > 4 jug/ml). Most strains of Pseudomonas spp., Serratia marcescens, Enterobacter spp., Hafnia alvei and Bacteroides spp. were resistant to RU29246.
RU29 246 killed Escherichia coli and Staphylococcus aureus at a rate of 99%to 99.9%at concentrations of two times MIC. The pH value of the medium (range 5.5 to 8.5) and the inoculum size (range 105 to 107cfu/ml) had no or only low influence on the antibacterial activity of RU29 246. RU29 246 is a broad spectrum cephalosporin including in its activity both Gram-positive and Gram-negative pathogens and therefore-depending on the bioavailability of its prodrug-looks promising as to its therapeutic perspective.
RU 29 246 (7-j8-[[2<2-aminothiazol-4 -yl)-2-^«-oximino]acetamido]ceph-3-em-3-methoxymethyl-4-carboxylic acid, Fig. 1 ) is a new cephem-antibiotic which has been esterified as the pivaloyl-oxyethyl-ester HR 916. RU29 246 is characterized by a methoxymethyl-group at the 3-position of the cephem nucleus. Due to its low absorption in the gastrointestinal tract the compound is-like most of the structurally related cephalosporins of the third generation-not suitable for oral administration. Esterification of the carboxyl-group, a prodrug approach successful previously with penicillins and other cephalosporins, increases lipophilicity which is one of the factors involved in the absorption of drugs in the gastrointestinal tract1~7).
In this study, the in vitro activity of RU 29 246 506 THE JOURNAL OF ANTIBIOTICS APR. 1992 and representative other oral cephalosporins such as cefdinir (FK482, Fujisawa), cefpodoxime (CS-807, Sankyo) , ceflxime (FK027, Fujisawa), ceftibuten (7432S, Shionogi), cefuroxime (Glaxo) and cefaclor (Lilly) were compared by their MICs. In addition, the bactericidal activity of RU29 246 was evaluated against representative strains. Furthermore, the influence of inoculum size and pH value of the medium on the MICs were investigated.
Materials and Methods
Strains Test Strains: The MICsof 1,220 isolates of 84 species were determined. The isolates were cultured from specimens of blood, sputum and urine, and from swabs of woundsites, ears, noses and throats. Only one isolate was accepted from each patient.
Bactericidal kinetics, influence of inoculum size and pH value were determined with strains from methicillin-resistant Staphylococci were incubated for a 24-hour period at 32°C and supplemented by 2% NaCl. After incubation the MICof each antibiotic was determined. The MICwas defined as the lowest concentration of antibiotic at which no visible growth or growth of <3 colonies was observed. Staphylococcus aureus ATCC29213, Escherichia coli ATCC25922 and Pseudomonas aeruginosa ATCC 27853 were used as reference strains.
Influence of the Inoculum Size
The influence of the inoculum size on the activity of RU29 246 was determined using a serial dilution test in Mueller-Hinton broth (Difco). Three simultaneously prepared geometric dilution series of the compound were inoculated with different suspensions of the test organisms. The initial numbers of viable bacteria were approximately 105, 106 and 107cfu/ml. Staphylococcus aureus SG 511, Escherichia coli 1507 E,.Enterobacter cloacae 1321 E and Klebsiella pneumoniae 1522 E served as representative pathogens. The effect of inoculum size was also investigated with 7 strains producing a plasmid-coded /Mactamase {Staphylococcus aureus 503, Escherichia coli TEM-1, TEM-2, OXA-1, OXA-2, OXA-3, SHV-1) and 2
strains producing a chromosomally coded /Mactamase {Klebsiella pneumoniae 1082 E, Citrobacter diversus 2046 E).
Influence of the pH Value of the Culture Medium
The effect of the pH value on the activity of RU29 246 was determined in Brain Heart Infusion medium (Difco), which had been adjusted to different pH values between 5.5 and 8.5. Inoculum size in colony forming units per ml. S. cohnii (10) S. saprophyticus (9) S. wameri (4) Enterococcus faecalis (20) E. faecium (17) E. liquefaciens (13 >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  >64  64  >64  32  >64  >64  >64  >64  64  >64  64  >64  >64  >64  >64  >64  >64  >64  >64 Helicobacter pylori ( 1 2) Clostridium difficile ( 1 2) Clostridium spp. (5) (1 C. sordelli, highest activity against Streptococcus pneumoniae followed by cefdinir and cefixime, while cefaclor and ceftibuten were the least active of the cephalosporins included. Penicillin-resistant Streptococcus pneumoniae were much less susceptible to all compoundsin comparison with the penicillin-susceptible strains (between 8 and 256 times). Strains of the Streptococcus milled group and of Streptococcus mitior were about equally susceptible to RU 29 246, cefdinir, cefpodoxime and cefuroxime (MIC90 0.13 to 0.25/jg/ml), but had MIC90sof 4 jug/ml or above for cefixime, ceftibuten and cefaclor. The MIC90 for hemolytic Streptococci of groups A, C and G were within a narrow range for RU 29 246, cefdinir and cefuroxime (0.016-0.06fig/ml).
Cefaclor (MIC90 0.13~0.25/ig/ml), cefixime VOL.45 NO.4 THE JOURNAL OF ANTIBIOTICS 517 (MIC90 0.25 /ig/ml) and particularly ceftibuten (MIC90 1^g/ml) were less active. Among the hemolytic Streptococci those of group B were less susceptible in comparison with the strains of groups A, C and G against all of the oral cephalosporins investigated except for RU29 246 which demonstrated an equal MIC90(0.06/ig/ml) both for group A and group B hemolytic Streptococci. The lower susceptibility of group B Streptococci in comparison with Streptococci of groups A, C and G was most pronounced for cefaclor and ceftibuten.
AmongEnterobacteriaceae the acivity of the oral cephalosporins was highest against a group of species composed of Escherichia coli, Klebsiella spp., Enterobacter sakazakii, Ptoteus mirabilis^Salmonella spp.
and Shigella spp. These species were highly susceptible (MIC90 <0.5iig/m\) to ceftibuten, cefixime, cefpodoxime, cefdinir and RU 29 246, but less susceptible to cefaclor (MIC90 0.5~8fig/m\) and cefuroxime (MIC90 4 -8 ;ug/ml). Proteus vulgaris was less susceptible than Proteus mirabilis (cefpodoxime three log2, RU29 246 seven log2, cefdinir eight log2, cefuroxime and cefaclor more than five log2) except for cefixime and ceftibuten, which were equally active against both species. These two compounds also inhibited both Providencia spp. at low concentrations, while the activities of cefpodoxime, cefdinir and RU29 246 were moderate and cefaclor was inactive against both species. Cefuroxime activity was intermediate against Providencia rettgeri and Providencia stuartii. Morganella morganii showed high MIC90 for all compounds (32//g/ml or above). However, a remarkable difference was observed at the MIC50 level for ceftibuten (0.25/zg/ml), cefpodoxime (1^g/ml), cefixime (2/zg/ml) and RU 29 246 (8,ug/ml). Strains of Serratia spp. were highly susceptible to ceftibuten, moderately susceptible to cefdinir, cefpodoxime and cefixime, while RU29 246, cefuroxime and cefaclor were mostly inactive. Citrobacter freundii was about equally susceptible to cefdinir, cefpodoxime, cefixime, ceftibuten; RU 29 246 demonstrated intermediate activity, while cefuroxime and cefaclor were inactive. Yersinia enterocolitica was about equally susceptible to all compounds, ceftibuten, however, was the most active agent. Hafnia alvei was resistant to all coumpounds (MIC90 equal to or above 32jUg/ml) except for ceftibuten (MIC90 8/ig/ml). For
Enterobacter spp. MIC90of all oral cephalosporins were equal to or above 64/zg/ml, ceftibuten being still the most active compound (MIC50 of 0.5 /zg/ml for Enterobacter cloacae and Enterobacter aerogenes). Against Acinetobacter baumannii only RU 29 246 (MIC90 8//g/ml) and cefdinir (MIC90 4/xg/ml) demonstrated marginal activities. Acinetobacter Iwoffi was in addition moderately susceptible to all the other compoundsexcept cefixime and cefaclor. All the oral cephalosporins included were inactive against the six species of Pseudomonas investigated.
MICs for each of the seven compounds investigated were mostly identical for Haemophilus influenzae and Haemophilusparainfluenzae. The activity of the oral cephalosporins included against ampicillin-resistant Haemophilus influenzae was equal to or only 2 to 4 times below that against ampicillin-susceptible isolates. Cefpodoxime,cefixime and ceftibuten were the most active compoundsagainst Haemophilusspp. (MIC90 0.06-0.25 jig/ml), followed by RU 29 246, cefdinir and cefuroxime (MIC90 0.25-1 /zg/ml) and cefaclor (MIC90 16 -32 ;ug/ml). Moraxella catarrhalis was equally susceptible to RU 29 246, cefdinir, cefpodoxime and cefixime, while ceftibuten, cefuroxime and cefaclor were 4 to 8 times less active.
Neisseria gonorrhoeae were about equally susceptible to RU 29 246, cefdinir and cefpodoxime (MIC90 0.03-0.06//g/ml), while cefixime was about twice as active (MIC90 0.016-0.03/ig/ml). Cefuroxime and ceftibuten were less active. Neisseria gonorrhoeae resistant to benzylpenicillin had MIC90only double as high as the penicillin-susceptible isolates except for cefuroxime (8 times higher). Cefixime was the most active oral cephalosporin against Neisseria gonorrhoeae, RU29 246, cefdinir and cefpodoxime being half as active as cefixime. Ceftibuten and cefuroxime were 16 to 32 times less active than cefixime. Cefaclor was the only one of the oral cephalosporins included without therapeutically relevant activity against the majority of Gonococci.
RU29 246, cefdinir and cefpodoxime were superior to the other compoundsin their activity against Brucella spp. Listeria spp. and Bordetella pertussis were resistant to all compoundsinvestigated.
Against Helicobacter pylori the in vitro activity of all cephalosporins was about equal, cefdinir, RU 29 246 and cefaclor being the most active compounds (MIC90 2/ig/ml). Among anaerobic pathogens {Clostridium difficile, Clostridium spp., Peptococcus magnus) RU 29 246 was the most active of the oral cephalosporins followed by cefuroxime and cefdinir, which were, however, totally inactive against Clostridium difficile. Activity against Bacteroides spp. was only moderate for all compounds (MIC90 > 16 /zg/ml).
Bactericidal
Activity The kinetics of killing of two Staphylococcus awrews-strains and two Escherichia co//-strains are shown in Figs. 2to 5.
Against Staphylococcus aureus SG 51 1 (Fig. 2) , RU 29 246 exhibited a bactericidal effect (killing of about 99%within 8 hours) at concentrations 2 times and 4 times the MIC, which was stronger with Staphylococcus aureus 503 (Fig. 3 , killing of between 99% and 99.9% within 8 hours). Exposure of both strains to a concentration equal to their MICwas bacteriostatic for Staphylococcus aureus SG51 1 and weakly bactericidal for Staphylococcus aureus 503 (killing of about 90% within 8 hours).
RU29 246 had only weak bactericidal activity at once the MIC against Escherichia coli 1507 E (Fig. 4) , concentrations of 2 times or 4 times the MICresulted in killing of more than 99% of the bacterial cells during the 8 hours test period. Against Escherichia coli TEM-1 (Fig. 5 ) the bacterial count was rapidly diminished at once, 2 times and 4 times the MIC. Four hours after introduction of RU29 246, however, at once the MICregrowth began, whereas killing proceeded at 2 times and 4 times the MIC. This regrowth was probably due to the degradation of RU29 246 by the TEM-10-lactamase, as the MIC of this strain remained unchanged until the end of the assay period.
Discussion
A broad variety of resorbable cephalosporins or cephalosporins made resorbable by esterification are now available for oral therapy8~10). Microbiological progress made by the newer compounds in comparison with e.g. cefuroxime and cefaclor includes both intrinsic activity (e.g. Haemophilus spp., Streptococci ) and thejr antibacterial spectrum (mostly within Enterobacteriaceae). Enhanced activity against Enterobacteriaceae for some of the neworal cephalosporins was achieved at the expense of low or no activity against Staphylococci (cefixime, cefetamet, ceftibuten). In this respect, these new compounds are inferior to established oral cephalosporins (e.g. cefuroxime-axetil). So, efforts are made to synthesize oral cephalosporins with improved activity against Staphylococci, e.g. cefprozil or Bay 35221O'11). Both compounds, however, are only moderately active against Enterobacteriaceae. A step forward to broad spectrum oral cephalosporins was achieved with cefdinir, cefpodoxime and RU29 246. RU29 246 in vitro activity is highly stable for a wide range of pH and inoculum size. RU29 246 possesses high activity against methicillin-susceptible Staphylococci, hemolytic Streptococci groups A, B, C and G and penicillin-susceptible Streptococcus pneumoniae similar to the activity of cefdinir, but superior to cefpodoxime, cefuroxime, ceftibuten, cefixime and also cefaclor. For most of the Gram-negative pathogens, MICs of RU 29 246 were higher than those of cefixime, cefpodoxime and ceftibuten. Nevertheless, MICs vs. the majority of strains of Escherichia coli, Klebsiella spp., Salmonella spp., Shigella spp. and Proteus spp. (MIC90 <0.5 /zg/ml) should allow successful therapy of infections caused by these organisms. The majority of Bacteroides spp. are resistant to RU29 246, whereas Gram-positive obligate anaerobes, even Clostridium difficile, are inhibited by relatively low concentrations (MIC90 < 8 /xg/ml). The activity of RU29 246 against these species is clearly superior to that of the reference compounds. Enterococci, Listeria spp. and Pseudomonas spp. are insensitive to all oral cephalosporins included. RU29 246 is bactericidal at concentrations of2 times and 4 times the MICkilling Escherichia coli and Staphylococcus aureus between 2 and 3 logs within 8 hours. Staphylococcus aureus SG5 1 1 is killed at a lower rate (between 1 and 2 logs).
So, RU 29 246 demonstrates broad spectrum in vitro activity including both Staphylococci and major Enterobacteriaceae. The bioavailability of its prodrug-ester HR916 will be decisive for the relevance of this new compounds in therapy.
